Veracyte (NASDAQ: VCYT)
Veracyte Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Veracyte Company Info
Veracyte Inc is engaged in the discovery, development, and commercialization of molecular cytology solutions that enable physicians to make more informed treatment decisions at an early stage in patient treatment.
News & Analysis
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?
The genetic test maker is rapidly increasing test volumes.
Here's Why This Little-Known Growth Stock Is a Buy
Analysts think this genomic test maker could have major upside in the next year.
Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors?
This diagnostics test maker has held up well over the last year.
Better Long-Term Buy in 2023: Exact Sciences or Veracyte?
As cancer screenings are becoming covered more often, both companies stand to gain.
This Small-Cap Stock Is a No-Brainer Buy
This genomic test maker's stock was beaten down in 2022. But it could be heading for a rebound this year.
Should Growth Investors Buy This Little-Known Stock?
Due to the downturn in the broader market, this genetic-testing stock has crashed so far this year.
3 Reasons to Buy This Sizzling Growth Stock
Veracyte appears to be an intriguing pick for growth investors to compound their wealth over the long run.
Is This Under-the-Radar Growth Stock a Buy?
This genetic diagnostics company could be a good pick for growth investors.
Valuation
Earnings Transcripts
Veracyte (VCYT) Q1 2020 Earnings Call Transcript
VCYT earnings call for the period ending March 31, 2020.
Veracyte (VCYT) Q4 2019 Earnings Call Transcript
VCYT earnings call for the period ending December 31, 2019.
Veracyte (VCYT) Q3 2019 Earnings Call Transcript
VCYT earnings call for the period ending September 30, 2019.
Veracyte (VCYT) Q2 2019 Earnings Call Transcript
VCYT earnings call for the period ending June 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.